Back to discover
Drug

Abicipar pegol

Approved medicine
ClassVascular endothelial growth factor A inhibitorResearchOngoing clinical research
RxNorm1941188ChEMBLCHEMBL4297684ATCS01LA07UNIIM55Q728KNA
VEGFA
Primary target
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Evaluation of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

Clinical trial2020-08-03Results posted · ClinicalTrials.gov

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)

Clinical trial2020-07-30Results posted · ClinicalTrials.gov

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)

Clinical trial2020-07-28Results posted · ClinicalTrials.gov

Evaluation of Safety and Systemic Pharmacokinetics After Abicipar Pegol (AGN-150998) Intravitreal Injections in Japanese Patients With NEovascular Age-Related Macular Degeneration (PINE Study)

Clinical trial2018-10-08Completed · ClinicalTrials.gov

Evaluation of Safety and Systemic Pharmacokinetics After Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration

Clinical trial2017-10-20Completed · ClinicalTrials.gov

A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration

Clinical trial2017-04-25Results posted · ClinicalTrials.gov

A Study of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

Clinical trial2016-05-17Results posted · ClinicalTrials.gov

A Study of Abicipar Pegol in Patients With Diabetic Macular Edema

Clinical trial2015-06-01Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Abicipar pegol
RxNorm CUI
1941188
ChEMBL ID
CHEMBL4297684
ATC codes
S01LA07
UNII
M55Q728KNA
Primary mechanism
Vascular endothelial growth factor A inhibitor

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

Vascular endothelial growth factor A, long form
VEGFA · P15692
INHIBITORVascular endothelial growth factor A inhibitor

Clinical trials

8 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
8
registered trials across all phases
LATEST COMPLETION 2019
2
Late-stage (III+)
8
Completed
PHASE DISTRIBUTIONn = 8
Phase 12Phase 24Phase 32

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)

CompletedPH IIIAllergann=9392019

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)

CompletedPH IIIAllergann=9492019

Recent completions

Trials that read out recently, adding to the completed evidence base.

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (CEDAR Study)

CompletedPH IIIAllergann=9392019

Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA Study)

CompletedPH IIIAllergann=9492019

Evaluation of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration

CompletedPH IIAllergann=1242019

Evaluation of Safety and Systemic Pharmacokinetics After Abicipar Pegol (AGN-150998) Intravitreal Injections in Japanese Patients With NEovascular Age-Related Macular Degeneration (PINE Study)

CompletedPH IAllergann=112018

Evaluation of Safety and Systemic Pharmacokinetics After Single and Repeat Doses of Abicipar Pegol (AGN-150998) Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration

CompletedPH IAllergann=302017

A Study of Abicipar Pegol in Japanese Patients With Neovascular Age-related Macular Degeneration

CompletedPH IIAllergann=252015
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials